Literature DB >> 15067325

DNA vaccination with CD25 protects rats from adjuvant arthritis and induces an antiergotypic response.

Avishai Mimran1, Felix Mor, Pnina Carmi, Francisco J Quintana, Varda Rotter, Irun R Cohen.   

Abstract

Ab's to the alpha-chain of the IL-2 receptor (anti-CD25) are used clinically to achieve immunosuppression. Here we investigated the effects of DNA vaccination with the whole CD25 gene on the induction of rat adjuvant arthritis. The DNA vaccine protected the rats and led to a shift in the cytokine profile of T cells responding to disease target antigens from Th1 to Th2. The mechanism of protection was found to involve the induction of an antiergotypic response, rather than the induction of anti-CD25 Ab's. Antiergotypic T cells respond to activation molecules, ergotopes, expressed on syngeneic activated, but not resting, T cells. CD25-derived peptides function as ergotopes that can be recognized by the antiergotypic T cells. Antiergotypic T cells taken from control sick rats did not proliferate against activated T cells and secreted mainly IFN-gamma. In contrast, antiergotypic cells from CD25-DNA-protected rats proliferated against activated T cells and secreted mainly IL-10. Protective antiergotypic T cells were found in both the CD4+ and CD8+ populations and expressed alpha/beta or gamma/delta T cell receptors. Antiergotypic alpha/beta T cells were MHC restricted, while gamma/delta T cells were MHC independent. Thus, CD25 DNA vaccination may induce protection from autoimmunity by inducing a cytokine shift in both the antiergotypic response and the response to the antigens targeted in the disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15067325      PMCID: PMC362112          DOI: 10.1172/JCI17772

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  54 in total

Review 1.  The IL-2 receptor complex: its structure, function, and target genes.

Authors:  Y Minami; T Kono; T Miyazaki; T Taniguchi
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

Review 2.  The IL-2/IL-2 receptor system: a current overview.

Authors:  T Taniguchi; Y Minami
Journal:  Cell       Date:  1993-04-09       Impact factor: 41.582

3.  Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts.

Authors:  J P Soulillou; D Cantarovich; B Le Mauff; M Giral; N Robillard; M Hourmant; M Hirn; Y Jacques
Journal:  N Engl J Med       Date:  1990-04-26       Impact factor: 91.245

4.  T cell vaccination in multiple sclerosis: a preliminary report.

Authors:  D A Hafler; I Cohen; D S Benjamin; H L Weiner
Journal:  Clin Immunol Immunopathol       Date:  1992-03

5.  Modulation of adjuvant arthritis in Lewis rats by recombinant vaccinia virus expressing the human 60-kilodalton heat shock protein.

Authors:  J A López-Guerrero; J P López-Bote; M A Ortiz; R S Gupta; E Páez; C Bernabeu
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

6.  MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination.

Authors:  J Zhang; R Medaer; P Stinissen; D Hafler; J Raus
Journal:  Science       Date:  1993-09-10       Impact factor: 47.728

Review 7.  The IL-2/IL-2 receptor system: a target for rational immune intervention.

Authors:  T A Waldmann
Journal:  Immunol Today       Date:  1993-06

8.  Induction of the anti-ergotypic response.

Authors:  A W Lohse; T W Spahn; T Wölfel; J Herkel; I R Cohen; K H Meyer zum Büschenfelde
Journal:  Int Immunol       Date:  1993-05       Impact factor: 4.823

9.  Differential mycobacterial 65-kDa heat shock protein T cell epitope recognition after adjuvant arthritis-inducing or protective immunization protocols.

Authors:  S M Anderton; R van der Zee; A Noordzij; W van Eden
Journal:  J Immunol       Date:  1994-04-01       Impact factor: 5.422

10.  Inhibition of adjuvant arthritis by a DNA vaccine encoding human heat shock protein 60.

Authors:  Francisco J Quintana; Pnina Carmi; Felix Mor; Irun R Cohen
Journal:  J Immunol       Date:  2002-09-15       Impact factor: 5.422

View more
  9 in total

Review 1.  Tregs in T cell vaccination: exploring the regulation of regulation.

Authors:  Irun R Cohen; Francisco J Quintana; Avishai Mimran
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

2.  Bilirubin suppresses Th17 immunity in colitis by upregulating CD39.

Authors:  Maria Serena Longhi; Marta Vuerich; Alireza Kalbasi; Jessica E Kenison; Ada Yeste; Eva Csizmadia; Byron Vaughn; Linda Feldbrugge; Shuji Mitsuhashi; Barbara Wegiel; Leo Otterbein; Alan Moss; Francisco J Quintana; Simon C Robson
Journal:  JCI Insight       Date:  2017-05-04

Review 3.  The mechanisms and applications of T cell vaccination for autoimmune diseases: a comprehensive review.

Authors:  Xin Huang; Haijing Wu; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2014-10       Impact factor: 8.667

4.  Therapeutic effect of ergotope peptides on CIA by down-regulation of inflammatory and Th1/Th17 responses and induction of regulatory T cells.

Authors:  Xiaoyin Niu; Shaohua Deng; Shan Li; Yebin Xi; Chengzhen Li; Li Wang; Dongyi He; Zhaojun Wang; Guangjie Chen
Journal:  Mol Med       Date:  2016-08-30       Impact factor: 6.354

5.  Oral and nasal administration of chicken type II collagen suppresses adjuvant arthritis in rats with intestinal lesions induced by meloxicam.

Authors:  Yong-Qiu Zheng; Wei Wei; Yu-Xian Shen; Min Dai; Li-Hua Liu
Journal:  World J Gastroenterol       Date:  2004-11-01       Impact factor: 5.742

6.  CD4+ regulatory T cell responses induced by T cell vaccination in patients with multiple sclerosis.

Authors:  Jian Hong; Ying C Q Zang; Hong Nie; Jingwu Z Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-17       Impact factor: 11.205

7.  Dynamic regulation of serum aryl hydrocarbon receptor agonists in MS.

Authors:  Veit Rothhammer; Davis M Borucki; Maria Isabel Garcia Sanchez; Maria Antonietta Mazzola; Christopher C Hemond; Keren Regev; Anu Paul; Pia Kivisäkk; Rohit Bakshi; Guillermo Izquierdo; Howard L Weiner; Francisco J Quintana
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-06-16

8.  HSP60 as a target of anti-ergotypic regulatory T cells.

Authors:  Francisco J Quintana; Avishai Mimran; Pnina Carmi; Felix Mor; Irun R Cohen
Journal:  PLoS One       Date:  2008-12-24       Impact factor: 3.240

9.  A cell-based drug delivery platform for treating central nervous system inflammation.

Authors:  Oren Levy; Veit Rothhammer; Ivan Mascanfroni; Zhixiang Tong; Rui Kuai; Michael De Biasio; Qingping Wang; Tahir Majid; Christelle Perrault; Ada Yeste; Jessica E Kenison; Helia Safaee; Juliet Musabeyezu; Martina Heinelt; Yuka Milton; Heidi Kuang; Haoyue Lan; William Siders; Marie-Christine Multon; Jonathan Rothblatt; Salam Massadeh; Manal Alaamery; Ali H Alhasan; Francisco J Quintana; Jeffrey M Karp
Journal:  J Mol Med (Berl)       Date:  2021-01-04       Impact factor: 4.599

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.